RTsafe’s Founder and Chief Scientific Officer, Dr. Evangelos Pappas, will also participate in a panel discussion on Personalized Cancer Care which will take place at 2:30pm on Tue, November 26th.
RTsafe today announced that its Personalized PseudoPatient™ product has received a 2019 R&D 100 Award from R&D World Magazine as one of the 100 most technologically significant products of the past year.
Single isocenter multi-focal stereotactic radiosurgery is a challenging treatment approach for multiple brain metastases. This study aims to experimentally quantify the overall spatial uncertainties of such treatment techniques.
RTsafe announces that Elekta is using RTsafe’s PseudoPatient™ technology for End-to-End stereotactic quality assurance (QA) in the new Elekta Assurance solution to deliver safe and efficient brain radiotherapy.
A research collaboration between RTsafe and Elekta resulted to the world’s first experimental quasi-real-time demonstration of dose accumulation during a clinical IMRT irradiation, a true breakthrough in radiotherapy.
